Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Clin Cancer Res. 2018 May 10;24(17):4332–4345. doi: 10.1158/1078-0432.CCR-18-0409

Figure 6.

Figure 6

BRCA2 null LuCaP organoids are hypersensitive to the PARP inhibitor olaparib, and carboplatin. A, Dose response curves for LuCaP 86.2 and LuCaP 86.2CR treated for two weeks with olaparib as quantified by CellTiter Glo 3D. Two independent experiments were performed. A representative figure is shown with error bars showing the standard error of the mean of five replicates. B, IC50 values calculated from dose response curves for the indicated LuCaP organoids treated with either olaparib or carboplatin. Error bars represent the standard error of the mean of two independent experiments.